Context

Hypoglycaemia is the primary limiting factor in the glycaemic management of diabetes.1 This is especially true of individuals with long-standing type 1 diabetes, who are at highest risk of severe hypoglycaemia due to the loss of counter-regulatory hormone responses and hypoglycaemic symptom awareness. Continuous glucose monitoring (CGM), using a subcutaneous sensor to frequently measure interstitial glucose, was developed as a tool for improving glycaemic control and reducing hypoglycaemia in diabetes. Recent studies have shown that real-time CGM can improve haemoglobin A1c (HbA1c)3 and reduce the duration of hyperglycaemia or hypoglycaemia over short periods in selected individuals.4 However, inherent problems have limited its effective use, …